BioSpace News Archive

Orbis and partners in the Vision 4 Africa consortium among high-scoring 100&Change applications featured in Bold Solutions Network

Aphena Pharma Solutions Inc. has announced the expansion of its bottling capacity with the purchase of a new, state-of-the-art, high-speed, solid-dose bottling line with an integrated cartoner.

Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin to optimize treatment for people living with diabetes, today announced positive results from its Phase 2 OPTI-1 study of injectable hepatocyte directed vesicle (HDV) added to mealtime insulin in people with type 1 diabetes (T1D).

InDex Pharmaceuticals Holding AB (publ) today announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis.

Adamas Pharmaceuticals, Inc. announced that the company will report 2019 fourth quarter financial results on Tuesday, February 25, 2020, after market close.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences

Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, was awarded with the 2020 Drug Hunter Award on February 11, 2020 by the UC Drug Discovery Consortium in a ceremony held at the University of California, San Francisco.

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2019.

Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2019.

Flowonix Medical, Inc. today announced United States Food and Drug Administration (FDA) approval to market the Prometra II Programmable Pump System for use with intrathecal baclofen. Flowonix introduced the Prometra II 40mL pump to the US market in November 2019,